NCT07021196

Brief Summary

Study evaluating the efficacy of ICT-based prescription of physical activity in oncology patients

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 17, 2024

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

May 26, 2025

Completed
18 days until next milestone

First Posted

Study publicly available on registry

June 13, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

June 13, 2025

Status Verified

September 1, 2024

Enrollment Period

1.3 years

First QC Date

May 26, 2025

Last Update Submit

June 6, 2025

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

  • tollerance to exercise

    10% increase in time of exercise

    6 months

Study Arms (1)

Patients affected by breast or prostatic cancer

Patients affected by breast or prostatic cancer eligible for adiuvant treatment

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients affected by breast or prostatic cancer eligible for adiuvant treatment

You may qualify if:

  • Female patients affected by breast cancer eligible for adiuvant treatment
  • Male patients affected by prostatic cancer eligible for adiuvant treatment

You may not qualify if:

  • Active life stily before enrollment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Federico II University

Naples, Italy

RECRUITING

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Guido Iaccarino, Full Professor

CONTACT

+390817463697afa.federico2@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

May 26, 2025

First Posted

June 13, 2025

Study Start

July 17, 2024

Primary Completion

October 31, 2025

Study Completion

December 1, 2025

Last Updated

June 13, 2025

Record last verified: 2024-09

Locations

IT(1)